Once-daily oral GLP-1 pills could fundamentally alter diabetes and obesity treatment in the Global South by lowering costs and removing the requirement for strict cold-chain refrigeration.
Medication that has served as a lifeline for patients with uncontrollable diabetes is slowly shifting from weekly injections to oral formulations, according to Al Jazeera. This transition alters both the management of metabolic disorders and global access to care. Market dominance has long belonged to injectables like Ozempic, Wegovy, and Mounjaro. Now, daily oral pills offer a viable alternative for regions where cold-chain logistics remain difficult to secure.
Key Terms for GLP-1 and Cold Chain Logistics
- Glucagon-like peptide-1 (GLP-1): A gut hormone that instructs the pancreas to release insulin as blood sugar rises while slowing stomach emptying to promote satiety.
- Cold Chain: Temperature-controlled supply chains required to maintain potency in injectable peptides and insulin.
- Oral Bioavailability: The fraction of an administered drug that reaches systemic circulation after surviving the digestive tract.
Global Prevalence and Regional Cost Disparities
One in nine people globally between the ages of 20 and 79 lives with diabetes, while one in eight is obese, as Al Jazeera reported. High price tags and exclusion from insurance coverage often relegate injectable therapies to elective status.
In the United States, Eli Lilly’s Mounjaro costs about $500 for a monthly supply, compared to £199 in the UK, 1,261 riyals in Saudi Arabia, and 14,766 rupees in India. In Pakistan, imported Mounjaro reaches 220,000 rupees, whereas locally manufactured tirzepatide from Getz Pharma costs 17,000 rupees.
Pakistan carries the highest diabetes prevalence globally at 31.4 percent of its population, followed by the Marshall Islands at 25.7 percent and Kuwait at 25.6 percent, according to Al Jazeera. Other heavily impacted nations include Samoa, Qatar, Kiribati, Saudi Arabia, French Polynesia, Egypt, and Bahrain. For many countries in the Global South, locally manufactured oral semaglutide priced at about $18 for a 30-day supply improves affordability and eliminates refrigeration demands in rural distribution networks.
Dr Zakir Alavi, an endocrinologist in Karachi, Pakistan, who has practiced for nearly 30 years, outlined the dual burden of malnutrition and metabolic disease.
“Pakistan is a country of contrast. We have, on one hand, childhood malnutrition, underweight, and stunted growth. On the other hand, we have childhood and adult obesity,” “And surprisingly, there is at least some element in the adult and childhood obesity which can be linked to a malnourished mother, and an underweight, premature baby,” Dr Zakir Alavi, an endocrinologist in Karachi, Pakistan, told Al Jazeera, adding that some adult and childhood obesity links back to malnourished mothers and underweight, premature infants.
Mechanisms of Action and Gut Hormone Discovery
The therapeutic journey began decades ago when Jens Juul Holst began investigating gut hormones. “When we discovered this, what we found was an insulin-releasing peptide from the gut,” Jens Juul Holst told Al Jazeera. Holst and his team sought to identify physiological mechanisms regulating blood glucose to address reactive hypoglycemia. Their intravenous infusions of GLP-1 normalized blood glucose levels completely in patients with long-standing type 2 diabetes within four hours.
| Drug / Compound | Receptor Target | Administration Route | Clinical Benefit |
|---|---|---|---|
| Semaglutide | GLP-1 receptor | Weekly injection / Daily oral | Blood sugar control, weight loss, cardiovascular risk reduction |
| Tirzepatide | GLP-1 and GIP receptors | Weekly injection | Enhanced glycemic control and sustained weight reduction |
| Retatrutide | GLP-1, GIP, and glucagon receptors | Injectable (in trials) | Investigational multi-receptor agonist targeting advanced metabolic outcomes |
Injectable GLP medicines like tirzepatide and semaglutide maintain stronger clinical trial evidence for long-term weight loss and cardiovascular risk reduction. Semaglutide operates on a single receptor, comparable to a single-lane underpass guaranteeing limited traffic flow. Tirzepatide engages both GLP-1 and GIP receptors, functioning like an overhead bridge and underpass combined to streamline cellular signaling.
Rayaz Malik, a professor of medicine at Weill Cornell Medicine Qatar and senior consultant at Hamad Medical Corporation in Doha, said that research points to a threshold of approximately 15 kilograms of weight loss to achieve remission in type 2 diabetes.
| Country / Region | Diabetes Prevalence Rate | Local Brand Pricing (Monthly) |
|---|---|---|
| Pakistan | 31.4% | Up to 220,000 rupees (imported) / 17,000 rupees (local) |
| Marshall Islands | 25.7% | Varies by import channels |
| Kuwait | 25.6% | Standard regional pricing |
| Saudi Arabia | 23.1% | 1,261 riyals ($336) |
Overcoming Digestive Barriers in Oral Pharmacology
Oral GLP-1 formulations must pass through the harsh acidic environment of the stomach before absorption occurs, requiring fasting protocols and higher doses for older agents like oral semaglutide. Newer oral candidates such as orforglipron aim to bypass these administration hurdles by functioning without strict fasting requirements.
Meanwhile, pharmaceutical manufacturers anticipate the global GLP market to expand from $80 billion annually to $135 billion by 2030, supported by World Health Organization guidelines recognizing GLP-1 medications for long-term obesity management following a year where obesity accounted for 3.7 million deaths worldwide.
Medical Risks and When to Seek Physician Advice
Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 must avoid GLP-1 receptor agonists due to identified risks in rodent studies. Individuals with a history of severe gastrointestinal disease, acute pancreatitis, or hypersensitivity to peptide-based therapeutics require careful clinical evaluation.
Consult a physician immediately if experiencing severe, persistent abdominal pain radiating to the back, persistent vomiting, symptoms of severe hypoglycemia, or signs of an allergic reaction such as swelling of the face, lips, or tongue.
As research progresses toward longer-acting monthly formulations and expanded oral availability, clinical focus remains on balancing efficacy with regional distribution realities. “The clever way for treatment is to do what your human body is doing,” Malik told Al Jazeera, “And it’s transforming people’s lives.”
References
- World Health Organization. Guidelines on the long-term pharmacological management of obesity. (December 2025).
- Al Jazeera. Coverage on oral GLP-1 therapeutics and diabetes prevalence in the Global South.
